Who are Ammoxetine Hydrochloride Enteric-coated Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, Active bupropion + counseling, fluoxetine + Amfebutamone, Escitalopram+Mirtazapine, SPN-812 (600mg, QD), sibutramine, orlistat, diethylpropion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ammoxetine-hydrochloride-enteric-coated-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ammoxetine Hydrochloride Enteric-coated Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ammoxetine Hydrochloride Enteric-coated Tablets (Ammoxetine Hydrochloride Enteric-coated Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: norepinephrine reuptake inhibitor. Area: Psychiatry.

phase 2 norepinephrine reuptake inhibitor norepinephrine transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Ammoxetine Hydrochloride Enteric-coated Tablets (Ammoxetine Hydrochloride Enteric-coated Tablets) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ammoxetine Hydrochloride Enteric-coated Tablets TARGET	Ammoxetine Hydrochloride Enteric-coated Tablets	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	phase 2	norepinephrine reuptake inhibitor	norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
Active bupropion + counseling	Active bupropion + counseling	University of Wisconsin, Madison	marketed	Antidepressant (dopamine-norepinephrine reuptake inhibitor)	Dopamine transporter (DAT), Norepinephrine transporter (NET)
fluoxetine + Amfebutamone	fluoxetine + Amfebutamone	Shanghai Mental Health Center	marketed	SSRI + NDRI combination antidepressant	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
Escitalopram+Mirtazapine	Escitalopram+Mirtazapine	Ministry of Health & Welfare, Korea	marketed	Antidepressant combination (SSRI + NaSSA)	Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	Supernus Pharmaceuticals, Inc.	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
sibutramine, orlistat, diethylpropion	sibutramine, orlistat, diethylpropion	Pennington Biomedical Research Center	marketed	Antiobesity agents (combination)	Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (norepinephrine reuptake inhibitor class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Kwang-Ha Yoo · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ammoxetine Hydrochloride Enteric-coated Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/ammoxetine-hydrochloride-enteric-coated-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab